These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 7730231)

  • 41. In vitro activity of rufloxacin against Listeria monocytogenes, Legionella pneumophila, and Chlamydia trachomatis.
    Furneri PM; Bazzano M; Campo L; Cesana M; Tempera G
    Chemotherapy; 1994; 40(2):104-8. PubMed ID: 8131632
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp.
    Ridgway GL; Salman H; Robbins MJ; Dencer C; Felmingham D
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():31-4. PubMed ID: 9484871
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The bactericidal activity of levofloxacin compared with ofloxacin, D-ofloxacin, ciprofloxacin, sparfloxacin and cefotaxime against Streptococcus pneumoniae.
    George J; Morrissey I
    J Antimicrob Chemother; 1997 Jun; 39(6):719-23. PubMed ID: 9222040
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antibacterial properties of AM-1155, a new 8-methoxy quinolone.
    Hosaka M; Kinoshita S; Toyama A; Otsuki M; Nishino T
    J Antimicrob Chemother; 1995 Aug; 36(2):293-301. PubMed ID: 8522459
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Protective effects of sparfloxacin in experimental pneumonia caused by Chlamydia pneumoniae in leukopenic mice.
    Nakata K; Okazaki Y; Hattori H; Nakamura S
    Antimicrob Agents Chemother; 1994 Aug; 38(8):1757-62. PubMed ID: 7986006
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Minimal inhibitory concentrations of lomefloxacin and minocycline against drug-sensitive and drug-resistant isolates of M. tuberculosis compared on L-J and 7H11 media.
    Kamala T; Herbert D; Venkatesan P; Paramasivan CN
    Int J Lepr Other Mycobact Dis; 1997 Sep; 65(3):375-8. PubMed ID: 9401493
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In-vitro and in-vivo antibacterial activity of CFC-222, a new fluoroquinolone.
    Kim JH; Choi KH; Kim JW; Lee JH; Choi EC; Kim BK
    J Antimicrob Chemother; 1998 Feb; 41(2):223-9. PubMed ID: 9533464
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Further characterization of the in vitro and in vivo activity of ciprofloxacin against mycoplasmas.
    Furneri PM; Tempera G; Chiarenza A; Caccamo F; Speciale AM; Nicoletti G
    Chemioterapia; 1987 Oct; 6(5):346-9. PubMed ID: 3123079
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative in-vitro activity of sparfloxacin against genital pathogens.
    Perea EJ; Aznar J; Garcia-Iglesias MC; Pascual A
    J Antimicrob Chemother; 1996 May; 37 Suppl A():19-25. PubMed ID: 8737122
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Antibacterial activity of tosufloxacin against major organisms detected from patients with respiratory infections].
    Kobayashi I; Matsuzaki K; Omika K; Hasegawa M; Sato Y
    Jpn J Antibiot; 2007 Apr; 60(2):98-106. PubMed ID: 17612257
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anti-Mycobacterium leprae activity of several quinolones studied in the mouse.
    Pattyn SR
    Int J Lepr Other Mycobact Dis; 1991 Dec; 59(4):613-7. PubMed ID: 1666402
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In-vitro activity of four new fluoroquinolones.
    García-Rodríguez JA; García Sánchez JE; García García MI; Fresnadillo MJ; Trujillano I; García Sánchez E
    J Antimicrob Chemother; 1994 Jul; 34(1):53-64. PubMed ID: 7961215
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Resistance of Mycoplasma pneumoniae to erythromycin: a clinical case with severe pulmonary, cerebral and systemic complications.
    Clara F; Von Busch C; Goeddertz P; Novotna I
    J Chemother; 1989 Jul; 1(4 Suppl):411-3. PubMed ID: 16312462
    [No Abstract]   [Full Text] [Related]  

  • 54. The in-vitro activity of tosufloxacin, a new fluorinated quinolone, compared with that of ciprofloxacin and temafloxacin.
    King A; Bethune L; Phillips I
    J Antimicrob Chemother; 1991 Nov; 28(5):719-25. PubMed ID: 1663930
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro activity of the new quinolone lomefloxacin against Mycobacterium tuberculosis.
    Piersimoni C; Morbiducci V; Bornigia S; De Sio G; Scalise G
    Am Rev Respir Dis; 1992 Dec; 146(6):1445-7. PubMed ID: 1333738
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vitro and in vivo antichlamydial activities of newly developed quinolone antimicrobial agents.
    Kimura M; Kishimoto T; Niki Y; Soejima R
    Antimicrob Agents Chemother; 1993 Apr; 37(4):801-3. PubMed ID: 8494377
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [In vitro antimycobacterial activity of a new quinolone, NM394].
    Tomioka H; Sato K; Saito H
    Kekkaku; 1993 Aug; 68(8):517-20. PubMed ID: 8397311
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In-vitro activities of temafloxacin, tosufloxacin (A-61827) and five other fluoroquinolone agents.
    Barry AL; Jones RN
    J Antimicrob Chemother; 1989 Apr; 23(4):527-35. PubMed ID: 2745259
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990.
    Bauernfeind A
    J Antimicrob Chemother; 1993 Apr; 31(4):505-22. PubMed ID: 7605398
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [In vitro antibacterial activity of prulifloxacin, a new oral quinolone, and comparative susceptibility rate at clinical breakpoint MIC].
    Inoue M; Kuga A; Kaieda S; Hosaka M; Kitasato H; Sato Y; Okamoto R; Eda T; Hoshino K; Seto I
    Jpn J Antibiot; 2000 Sep; 53(9):593-608. PubMed ID: 11214999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.